PubMed ID:
25629445
Public Release Type:
Journal
Publication Year: 2015
Affiliation: 1 Clinical Islet Transplant Program, Division of Endocrinology, University of Alberta , Edmonton, Alberta, Canada .
DOI:
https://doi.org/10.1089/dia.2014.0289
Authors:
Senior PA,
Alejandro R,
Al-saden P,
Baidal D,
Bayman L,
Bellin MD,
Bernetti K,
Brandenburg M,
Bridges N,
Chaloner K,
Clarke WR,
Clinical Islet Transplantation Consortium,
Corrales AC,
Cure P,
Czarniecki C,
Dalton-Bakes C,
Diltz C,
Dinyari P,
Ecklund D,
Eggerman TL,
Faradji R,
Feddersen D,
Foster E,
Froud T,
George L,
Goldstein J,
Gorn L,
Green N,
Hecyk A,
Hering B,
Herrada E,
Hunsicker L,
Hutchinson J,
Jasperson C,
Johnson K,
Kaufman D,
Lafontant DE,
Lagari V,
Linetsky E,
Luo X,
Malcolm A,
Markmann E,
Markmann J,
Martellotto J,
McElroy J,
Molitch M,
Monroy K,
Mueller R,
Naji A,
Neill-Hudson T,
Nollen D,
Oberholzer J,
Palanjian M,
Pedersen J,
Peixoto E,
Poggioli R,
Ponte G,
Posselt A,
Priore A,
Qidwai J,
Qidwai JC,
Ramos M,
Rickels MR,
Ricordi C,
Riss H,
Robien MA,
Rojas T,
Sanderson J,
Schwieger T,
Schwieger TR,
Sears M,
Shapiro J,
Sherer K,
Shestokas E,
Smith D,
Stock P,
Stuart E,
Sutcliffe R,
Turgeon N,
Watson N,
White S,
Willits J,
Witson J,
Yankey JW
In long-standing type 1 diabetes (T1D), loss of endogenous insulin secretion and glucose dysregulation can lead to severe hypoglycemia and associated complications. Here, we report the serial consistency and the correlation between different scores that characterize glucose dysregulation using self-monitoring of blood glucose (SMBG), in a cohort of T1D individuals being evaluated for transplant eligibility in Clinical Islet Transplantation Consortium trials.